127 related articles for article (PubMed ID: 18201402)
21. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
[TBL] [Abstract][Full Text] [Related]
22. Triaging women with human papillomavirus infection and normal cytology or low-grade dyskaryosis: evidence from 10-year follow up of the ARTISTIC trial cohort.
Gilham C; Sargent A; Peto J
BJOG; 2020 Jan; 127(1):58-68. PubMed ID: 31541495
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Ghiringhello B; Girlando S; Gillio-Tos A; De Marco L; Naldoni C; Pierotti P; Rizzolo R; Schincaglia P; Zorzi M; Zappa M; Segnan N; Cuzick J;
Lancet Oncol; 2010 Mar; 11(3):249-57. PubMed ID: 20089449
[TBL] [Abstract][Full Text] [Related]
24. The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer.
Barrett JE; Sundström K; Jones A; Evans I; Wang J; Herzog C; Dillner J; Widschwendter M
Genome Med; 2022 Oct; 14(1):116. PubMed ID: 36258199
[TBL] [Abstract][Full Text] [Related]
25. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
26. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
[TBL] [Abstract][Full Text] [Related]
27. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.
Kitchener HC; Almonte M; Thomson C; Wheeler P; Sargent A; Stoykova B; Gilham C; Baysson H; Roberts C; Dowie R; Desai M; Mather J; Bailey A; Turner A; Moss S; Peto J
Lancet Oncol; 2009 Jul; 10(7):672-82. PubMed ID: 19540162
[TBL] [Abstract][Full Text] [Related]
28. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
29. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,
Bratti MC; Rodríguez AC; Schiffman M; Hildesheim A; Morales J; Alfaro M; Guillén D; Hutchinson M; Sherman ME; Eklund C; Schussler J; Buckland J; Morera LA; Cárdenas F; Barrantes M; Pérez E; Cox TJ; Burk RD; Herrero R
Rev Panam Salud Publica; 2004 Feb; 15(2):75-89. PubMed ID: 15030652
[TBL] [Abstract][Full Text] [Related]
30. CIN 2/3 and cervical cancer in an organised screening programme after an unsatisfactory or a normal Pap smear: a seven-year prospective study of the Norwegian population-based screening programme.
Nygård JF; Sauer T; Nygård M; Skare GB; Thoresen SØ
J Med Screen; 2004; 11(2):70-6. PubMed ID: 15153321
[TBL] [Abstract][Full Text] [Related]
31. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
[TBL] [Abstract][Full Text] [Related]
32. [Three-year follow-up results of visual inspection with acetic acid/Lugol's iodine (VIA/VILI) used as an alternative screening method for cervical cancer in rural areas].
Zhang YZ; Ma JF; Zhao FH; Xiang XE; Ma ZH; Shi YT; Hu SY; Qiao YL
Chin J Cancer; 2010 Jan; 29(1):4-8. PubMed ID: 20038302
[TBL] [Abstract][Full Text] [Related]
33. Monitoring and evaluation of a model demonstration project for the control of cervical cancer in Nakhon Phanom province, Thailand.
Deerasamee S; Srivatanakul P; Sriplung H; Nilvachararung S; Tansuwan U; Pitakpraiwan P; Kaewkungwal J; Singhasivanon P; Nimnakorn P; Sankaranarayanan R
Asian Pac J Cancer Prev; 2007; 8(4):547-56. PubMed ID: 18260727
[TBL] [Abstract][Full Text] [Related]
34. Quality of colposcopy and treatment: data from the national survey of Italian organised cervical screening programmes.
Volante R; Giubilato P; Ronco G
Epidemiol Prev; 2007; 31(2-3 Suppl 2):61-8. PubMed ID: 17824363
[TBL] [Abstract][Full Text] [Related]
35. Establishment of a national cervical screening programme in Ireland, CervicalCheck: the first 6 years.
Flannelly GM; Mooney MT; Greehy GM; Keogh EB; McNally SA; Fitzpatrick PE
Eur J Cancer Prev; 2018 Mar; 27(2):158-163. PubMed ID: 27824660
[TBL] [Abstract][Full Text] [Related]
36. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study.
Canfell K; Barnabas R; Patnick J; Beral V
Br J Cancer; 2004 Aug; 91(3):530-6. PubMed ID: 15266332
[TBL] [Abstract][Full Text] [Related]
37. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
Cleveland AA; Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Saadeh K; Pemmaraju M; Higgins K; Ehlers S; Scahill M; Johnson Jones ML; Querec T; Markowitz LE; Unger ER;
Int J Cancer; 2020 Feb; 146(3):810-818. PubMed ID: 30980692
[TBL] [Abstract][Full Text] [Related]
38. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening.
Kitchener HC; Almonte M; Gilham C; Dowie R; Stoykova B; Sargent A; Roberts C; Desai M; Peto J;
Health Technol Assess; 2009 Nov; 13(51):1-150, iii-iv. PubMed ID: 19891902
[TBL] [Abstract][Full Text] [Related]
39. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
[TBL] [Abstract][Full Text] [Related]
40. Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009-2012.
Watson M; Soman A; Flagg EW; Unger E; Deapen D; Chen VW; Peres LC; Copeland G; Tucker TC; Garnett E; Saraiya M
Prev Med; 2017 Oct; 103():60-65. PubMed ID: 28765084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
